Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Reviews in Endocrine & Metabolic Disorders|November 6, 2024
GHRH and the prostateLaura Muñoz-Moreno, Irene D Román, Ana M Bajo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancersAna M Bajo, Andrew V Schally, Gabor Halmos, et al.
Molecular and Cellular Endocrinology|September 8, 2011
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cellsAna Valdehita, María J Carmena, Ana M Bajo, et al.
Molecular and Cellular Endocrinology|February 15, 2017
Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cellsLaura Muñoz-Moreno, Ana M Bajo, Juan C Prieto, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 22, 2025
Fundamentals of Zymography: Applications to the Study of Biological SamplesJorge Recio-Aldavero, Laura Muñoz-Moreno, I Dolores Román, et al.
Bioscience Reports|January 30, 2004
Solubilization of adenylyl cyclase from human myometrium in a alphas-coupled formAna M Bajo, Juan C Prieto, Pedro Valenzuela, et al.
Peptides|June 5, 2007
Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft modelBeatriz Collado, María J Carmena, Celia Clemente, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 23, 2003
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancersMarkus Letsch, Andrew V Schally, Rebeca Busto, et al.
Regulatory Peptides|August 9, 2007
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cellsAna Valdehita, María J Carmena, Beatriz Collado, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2002
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenesAna M Bajo, Andrew V Schally, Magdalena Krupa, et al.
Pageof 5